SNTA1

Across TCGA pan-cancer cohorts, SNTA1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SNTA1 data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SNTA1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SNTA1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where SNTA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.859	0.655	.001	19	view →
HNSC	DFS	Median	All	0.680	0.848	.009	12	view →
LUAD	DFS	Median	All	0.895	0.476	.003	10	view →
CCRCC	OS	Median	IV	0.785	0.123	.009	5	view →
UCEC	DFS	Median	All	0.908	0.797	.049	2	view →
GBM	OS	Quartile	All	0.272	0.604	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SNTA1–PDAC (DFS)

Open the PDAC breakdown →